Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008

-Advances Reported in All Three Clinical Programs, Including Launch of Key

Bavituximab Phase II Cancer Program-

TUSTIN, Calif., March 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced financial results for the third quarter of fiscal year (FY) 2008 ended January 31, 2008. The company reported a consolidated net loss of $6,154,000, or $0.03 per basic and diluted share, compared to a consolidated net loss of $5,025,000 or $0.03 per basic and diluted share for the same prior year period. The increased net loss primarily reflects increased investments in research and development as the company advanced its clinical programs for bavituximab and Cotara(R).

Total revenues for the current quarter increased to $1,675,000 compared to $363,000 for the comparable quarter last year, and were primarily generated from services provided by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

Total costs and expenses increased to $8,077,000 in the third quarter of FY 2008 from $5,643,000 in the same prior year quarter. The increase was primarily related to the increase in the cost of contract manufacturing of $1,066,000 during the quarter resulting from higher reported revenues from external customers, in addition to the increase in research and development expenses of $1,034,000 associated with the advancement of the company's clinical and preclinical product candidates. Research and development expenses were $4,941,000 in the third quarter of FY 2008, compared to $3,907,000 in the third quarter of FY 2007 8,077,000 5,643,000 23,035,000 17,939,000


OPERATIONS (6,402,000) (5,280,000) (17,843,000) (16,471,000)



Interest and

other income 259,000 267,000 851,000 955,000

Interest and

other expense (11,000) (12,000) (25,000) (36,000)

NET LOSS $(6,154,000) $(5,025,000) $(17,017,000) $(15,552,000)




Basic and

Diluted 226,210,617 195,299,586 219,497,601 191,067,145



SHARE $(0.03) $(0.03) $(0.08) $(0.08)

. At January 31, 2008, the company had $20,063,000 in cash and cash equivalents compared to $16,044,000 at fiscal year end April 30, 2007.

"The past quarter was highlighted by a major milestone in our oncology program, as we dosed the first patients in a Phase II trial evaluating bavituximab in combination with chemotherapy in patients with breast cancer," said Steven W. King, president and CEO of Peregrine. "We also received regulatory approval to initiate two additional bavituximab Phase II cancer trials -- a second breast cancer study and a trial in patients with non-small cell lung cancer, a leading cause of cancer deaths worldwide. Planning for these trials is well underway and we anticipate initiating both studies next month. We also made progress in our Cotara clinical program in patients with glioblastoma multiforme (GBM), today announcing promising data from the ongoing dosimetry and Phase II trials showing that several patients are already surviving longer than the expected six-month median survival time for this patient population, with the longest surviving patient now at 15 months post-treatment. Patients who are continuing in the trials are being monitored for safety and overall survival, and we look forward to providing further updates on these trials going forward. We have also recently expanded the number of clinical sites in the Phase Il study to eight and also added a distinguished brain cancer center and experienced Cotara clinical study site -- the Barrow Neurological Institute -- to our dosimetry study in the U.S."

Mr. King added, "Our initiative to raise awareness for the bavituximab and Cotara programs in the scientific and medical communities scored gains, including an oral presentation covering the clinical experience to date in the bavituximab Phase I cancer program at Angio 2008, an oral presentation of clinical data from our Phase I bavituximab trial in hepatitis C patients at the prestigious 2007 Liver Meeting(R), a recent publication in Clinical Cancer Research highlighting bavituximab's ability to target tumor blood vessels with excellent specificity, and the acceptance last week of an abstract discussing patient data from the Cotara dosimetry trial for presentation at the 2008 ASCO Annual Meeting. We anticipate additional high profile scientific publications and presentations in the coming months while we continue making good progress in advancing our trio of Phase II bavituximab cancer trials, the two ongoing Cotara clinical trials and the trial of bavituximab in HCV patients co-infected with HIV. We look forward to a steady flow of news from these multiple activities in the coming months."

Recent Highlights

Bavituximab Anti-Cancer Program: The company launched the Phase II cancer clinical program for bavituximab during the quarter and achieved a number of other clinical and preclinical advancements.
-- Initiated patient dosing in a Phase II combination therapy trial of

bavituximab and docetaxel in patients with advanced breast cancer

within 14 days of study initiation.

-- Received regulatory approval to begin two additional Phase II

bavituximab combination therapy trials -- one in combination with

carboplatin and paclitaxel in patients with advanced breast cancer and

another in combination with carboplatin plus paclitaxel in patients

with non-small cell lung cancer (NSCLC). Both trials are preparing to

begin enrolling patients shortly.

-- A bavituximab cancer investigator presented data at a leading

scientific meeting on anti-angiogenic agents -- the 10th Annual

International Symposium on Anti-Angiogenic Agents (Angio 2008) --

highlighting the positive clinical experience to date with


-- A preclinical study published in Clinical Cancer Research confirmed

bavituximab's ability to target tumor blood vessels with excellent

specificity. The high degree of selective targeting seen in the study

provides additional evidence of bavituximab's therapeutic potential.

Bavituximab Anti-Viral Program: During the third quarter, the company continued to advance its bavituximab HCV program and presented positive data at a key liver disease meeting.
-- Added The Johns Hopkins Hospital and a private clinic in Orange

County, California as additional clinical study sites for the HCV/HIV

co-infection study.

-- Presented final results from the Phase I multiple dose HCV trial at

the prestigious Annual Meeting of the American Association for the

Study of Liver Disease that showed bavituximab was well tolerated and

demonstrated encouraging signs of anti-viral activity.

Cotara(R) Glioblastoma Program: Peregrine continued to advance the Cotara brain cancer program.
-- Added additional study sites and continued patient dosing and

follow-up in the Cotara Phase II study in patients with glioblastoma

multiforme, the most deadly form of brain cancer. Eight sites are now

open for patient enrollment.

-- Added an additional site, the Barrow Neurological Institute (BNI) in

Phoenix, Arizona, to the ongoing Cotara dosimetry and dose

confirmation clinical study. BNI also participated in a previous

Cotara Phase II clinical trial.

-- Announced positive results from the first cohort of patients treated

in the Cotara dosimetry trial and from the initial patients treated in

the Cotara Phase II trial. Cotara appeared safe and well tolerated

with no dose-limiting adverse events, with continuing patients being

monitored for overall survival. Several patients in these studies

have lived longer than the six-month expected median survival time for

this patient population.

Other Preclinical Programs:

-- Preclinical data presented at the 5th Annual International

Anti-Angiogenesis Conference confirmed that Peregrine's fully human,

selective anti-VEGF antibody R84 was as effective as Avastin(R) in

inhibiting tumor growth in a model of human breast cancer. Selective

anti-VEGF agents may have potential advantages over non-selective


Avid Bioservices:

-- Wholly owned manufacturing subsidiary Avid Bioservices signed an

agreement with ARIUS Research to produce clinical supplies of their

lead cancer stem cell anti-CD44 antibody.

-- Avid continued to demonstrate strong revenue performance during the

third quarter of fiscal year 2008.

Conference Call

The company will host a conference call today, March 11, 2008 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its third quarter FY 2008 financial results.

To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: The webcast will be archived on Peregrine's website for approximately 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 18, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (, which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company may experience delays in clinical trial patient enrollment, the risk that future clinical trial results may not correlate with the results of prior clinical trials and preclinical studies, the risk that Avid's revenue growth may slow or decline, the risk that future protocol submissions may not be approved, the risk that the company may not be able to monetize any of its assets, the risk that the company will not regain compliance with the Nasdaq Stock Market minimum bid price requirement by July 21, 2008, and the risk that the company will not have additional high profile scientific publications and presentations. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the third fiscal quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


GendeLLindheim BioCom Partners

Investors Media Barbara Lindheim

(800) 987-8256 (212) 918-4650

-financial tables to follow-




2008 2007




Cash and cash equivalents $20,063,000 $16,044,000

Trade and other receivables 1,316,000 750,000

Inventories, net 2,394,000 1,916,000

Prepaid expenses and other current assets 1,140,000 1,188,000

Total current assets 24,913,000 19,898,000


Leasehold improvements 669,000 646,000

Laboratory equipment 3,756,000 3,533,000

Furniture, fixtures and office equipment 913,000 873,000

5,338,000 5,052,000

Less accumulated depreciation and

amortization (3,537,000) (3,212,000)

Property, net 1,801,000 1,840,000

Other assets 1,527,000 1,259,000

TOTAL ASSETS $28,241,000 $22,997,000




2008 2007




Accounts payable $2,387,000 $1,683,000

Accrued clinical trial site fees 244,000 228,000

Accrued legal and accounting fees 390,000 392,000

Accrued royalties and license fees 124,000 337,000

Accrued payroll and related costs 858,000 874,000

Notes payable, current portion - 379,000

Capital lease obligation, current portion 17,000 17,000

Deferred revenue 1,434,000 1,060,000

Other current liabilities 1,239,000 885,000

Total current liabilities 6,693,000 5,855,000

Notes payable, less current portion - 119,000

Capital lease obligation, less current portion 17,000 30,000

Deferred license revenue - 4,000

Commitments and contingencies


Preferred stock-$.001 par value;

authorized 5,000,000 shares; non-voting;

nil shares outstanding - -

Common stock-$.001 par value; authorized

325,000,000 shares; outstanding -

226,210,617 and 196,112,201, respectively 226,000 196,000

Additional paid-in capital 245,982,000 224,453,000

Accumulated deficit (224,677,000) (207,660,000)

Total stockholders' equity 21,531,000 16,989,000





January 31, January 31, January 31 January 31,

2008 2007 2008 2007

Unaudited Unaudited Unaudited Unaudited




revenue $1,662,000 $347,000 $5,146,000 $1,381,000

License revenue 13,000 16,000 46,000 87,000

Total revenues 1,675,000 363,000 5,192,000 1,468,000


Cost of contract

manufacturing 1,289,000 223,000 3,872,000 1,247,000

Research and

development 4,941,000 3,907,000 13,665,000 11,868,000

Selling, general

and administrative 1,847,000 1,513,000 5,498,000 4,824,000

Total costs

and expenses

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
(Date:10/9/2017)... , ... October 09, 2017 , ... At its national ... Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been ... a member of the winning team for the 2015 Breakthrough Prize in Fundamental physics ...
Breaking Biology Technology:
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
Breaking Biology News(10 mins):